La cadena de opciones muestra datos clave de las opciones de acciones de Sutro Biopharma a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Sutro Biopharma..

Sutro Biopharma (NASDAQ:STRO) Bolsa, Cadena de Opciones

SUTRO BIOPHARMA INC

Sutro Biopharma

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

Sutro Biopharma Inc

Strong

STROEER SE CO UNSP/ADR by Stroeer SE and Co

Stroeer SE & Co KGaA

Stronghold Digital Mining Inc

Stronghold Token

STROUD RESOURCES LTD by Stroud Resources Ltd.

Stroud Resources Ltd

Earnings

Press Releases

Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights

News

Health Care

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025

Small Cap

Opinion

New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty

Sutro Biopharma to Participate in Upcoming Investor Conferences

Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

Management

Sutro Biopharma Appoints Greg Chow as Chief Financial Officer

Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights

FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone

Penny Stocks

Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones

AGEN

BCTX

CSTL

IBRX

ONCY

STRO

TSX:BCT

TSX:ONC

ABVC BioPharma

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Aligos Therapeutics

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

BeyondSpring

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Cibus

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

CervoMed

Cue Biopharma

CEL-SCI

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Gain Therapeutics

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

ImmuCell

MiNK Therapeutics

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

OS Therapies

PMV Pharma

Plus Therapeutics

Pelthos Therapeutics

Repare Therapeutics

X4 Pharmaceuticals

Wells Fargo

Piper Sandler

B of A Securities

HC Wainwright & Co.

Comments

Sutro Biopharma

Sutro Biopharma (STRO) Opciones

Sutro Biopharma (NASDAQ:STRO) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL